Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

MLSS US Equity

Milestone Scientific Inc.Health Care · Orthopedic, Prosthetic & Surgical Appliances & Supplies · CIK 855683 · FY ends Dec 31
$0.47
-0.02 (-4.65%)
USD · as of 2026-08-19 · marketstack

Legal & controls

5 of 5 annual reports readable here

Item 3 and Item 9A as filed · every verdict is the registrant’s own sentence, printed below it · a filing that fails an extraction gate reads “not extracted”

Fiscal yearFiledItem 3ICFRdisclosure controlsmaterial weaknessFiling
2025-12-312026-03-31as filedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · We are not involved in any legal proceedings.

Item 9A · ICFR · Based on this assessment, management concluded that, as of December 31, 2025, the Company’s internal control over financial reporting was effective.

Item 9A · disclosure controls · Based on this evaluation, the Chief Executive Officer and Vice President of Finance concluded that, as of December 31, 2025, the Company’s disclosure controls and procedures were effective at the reasonable assurance level.

2024-12-312025-04-15none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · Milestone Scientific is not involved in any material litigation.

Item 9A · ICFR · Based on this assessment, management concluded that, As of December 31, 2024, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based on such evaluation, our Interim Chief Executive Officer and Acting Principal Accounting Officer concluded that, As of December 31, 2024, our disclosure controls and procedures were effective at a reasonable assurance level.

2023-12-312024-03-29none statedeffectiveeffectivenone in Item 9AEDGAR

Item 3 · Milestone Scientific is not involved in any material litigation.

Item 9A · ICFR · Based on this assessment, management concluded that, as of December 31, 2023, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based on such evaluation, our Chief Executive Officer, and Principal Accounting Officer, concluded that, as of December 31, 2023, our disclosure controls and procedures were effective at a reasonable assurance level.

2022-12-312023-03-30none statedeffectiveeffectiveremediated (prior year)EDGAR

Item 3 · Milestone Scientific is not involved in any material litigation.

Item 9A · ICFR · Based on this assessment, management concluded that, as of December 31, 2022, our internal control over financial reporting was effective.

Item 9A · disclosure controls · Based on this evaluation, our Chief Executive Officer, and Chief Financial Officer concluded that our disclosure controls and procedures (as defined in paragraph (e) of Rules 13a-15 and 15d-15 under the Exchange Act) were effective at December 31, 2022.

Item 9A · material weakness · Changes in Internal Control over Financial Reporting During the year ended December 31, 2022, the Company remediated the identified material weakness from December 31, 2021.

2021-12-312022-03-31none statedNOT effectivenot extracteddisclosedEDGAR

Item 3 · Milestone Scientific is not involved in any material litigation.

Item 9A · ICFR · Based on this evaluation, our Chief Executive Officer concluded that our disclosure controls and procedures (as defined in paragraph (e) of Rules 13a-15 and 15d-15 under the Exchange Act) were not effective as December 31, 2021 due to a material weakness in our internal control over financial reporting as described below and in Note F of the consolidated financial statements.

5 of 5 annual reports on record have their filing text cached on this host; the rest are listed with their EDGAR link and no extraction, because this surface never fetches from SEC on a page load.

  • Item 3 and Item 9A are located in the filing HTML already cached on this host and read with the same line-anchored item matcher and largest-gap body disambiguation the filing-narrative pass uses for Item 1A and Item 7 — no fetch, no model, no summarization.
  • A heading is accepted as a section only when it is not a table-of-contents row (a trailing page number), not a quoted reference in prose, and names its own section; the span must then clear a per-item length band and carry readable text after the heading. Anything that fails a gate is served as 'not extracted' with the reason — never as a default value.
  • An effectiveness conclusion is read only from a sentence that names its own control set (disclosure controls and procedures, or internal control over financial reporting) and states an outcome. Conditional sentences — the standard limitations paragraph and forward-looking remediation language — are excluded, because they are hypotheses rather than conclusions.
  • When a filing's own sentences disagree — an effective conclusion beside an unremediated material-weakness disclosure, or two conclusions of opposite sign — no verdict is asserted. A wrong 'controls were effective' reading is worse than no reading.
  • Every verdict is shown beside the verbatim sentence it was read from. The excerpt is the filing's own words, capped at 1,200 characters; the filing itself is one link away.